Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,178 JPY
Change Today -20.00 / -0.91%
Volume 1.6M
4151 On Other Exchanges
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/15 - ¥2,321
52 Week Low
01/7/15 - ¥1,094
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd., a research-based life sciences company, manufactures and markets pharmaceuticals and bio-chemicals in Japan and other Asian countries, Europe, the United States, and internationally. The company’s Pharmaceuticals segment manufactures and sells ethical drugs, including NESP/ESPO, an ESA formulation; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; CONIEL, a hypertension and angina pectoris; GRAN, a G-CSF product; DEPAKENE, an antiepileptic agent; NOURIAST, an antiparkinsonian agent; REGPARA, a calcium receptor agonist; Abstral, a treatment for managing cancer pain; Fentos, a transdermal product; ASACOL, an ulcerative colitis treatment; ONGLYZA for the treatment of type 2 diabetes; Romiplate, an idiopathic thrombocytopenic purpura and thrombopoietin receptor agonist; and POTELIGEO for relapsed CCR4-positive peripheral T-cell lymphoma, as well as Dovobet, a psoriasis vulgaris treatment; and G-Lasta for the treatment of chemotherapy induced febrile neutropenia. Its Bio-chemicals segment produces and sells amino acids, nucleotides vitamins, and sugars for use in pharmaceuticals, health foods, cosmetics, and other products. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sells fine chemicals; and is involved in mail-order sale of healthcare products. The company also engages in pharmaceuticals licensing, insurance, wholesale, and retail activities. Kyowa Hakko Kirin Co., Ltd. was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,424 Employees
Last Reported Date: 03/13/15
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Co., Ltd., Nine Months 2015 Earnings Call, Oct 28, 2015

Kyowa Hakko Kirin Co., Ltd., Nine Months 2015 Earnings Call, Oct 28, 2015

Kyowa Hakko Kirin Co., Ltd. Approves Partial Amendment to the Articles of Incorporation

Kyowa Hakko Kirin Co., Ltd. approved partial amendment to the articles of incorporation of the company, at the board of directors meeting held on October 28, 2015. Current text: Article 8. - The number of shares to constitute a unit share of the Company (Tangen-kabu) shall be 1,000. Amended text: Article 8. - The number of shares to constitute a unit share of the Company (Tangen-kabu) shall be 100. Effective January 1, 2016.

Kyowa Hakko Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2015

Kyowa Hakko Kirin Co., Ltd. provided dividend guidance for the year ending December 31, 2015. The company expects year end dividend of JPY 12.50 per share compared to paid dividend of JPY 12.50 per share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥2,178.00 JPY -20.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr892.50 DKK +17.00
ImmunoGen Inc $13.59 USD -0.17
Insys Therapeutics Inc $31.11 USD -1.71
MorphoSys AG €56.46 EUR +0.22
Seattle Genetics Inc $43.17 USD +0.96
View Industry Companies

Industry Analysis


Industry Average

Valuation 4151 Industry Range
Price/Earnings 38.9x
Price/Sales 3.2x
Price/Book 1.9x
Price/Cash Flow 21.9x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KYOWA HAKKO KIRIN CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at